Sichuan Goldstone Asia Pharmaceutical Inc. (SHE:300434)

SHE:300434 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	1,101	1,171	1,200	1,006	734.16	948.2
Other Revenue	38.09	38.09	42.79	47.74	43.14	57.4
Revenue	1,139	1,209	1,243	1,054	777.3	1,006
Revenue Growth (YoY)	-16.16%	-2.69%	17.95%	35.53%	-22.70%	3.59%
Cost of Revenue	475.42	467.17	480.74	459.56	359.85	358.14
Gross Profit	663.36	742.03	761.87	593.94	417.45	647.47
Selling, General & Admin	444.26	429.83	421.07	419.15	375.19	428.31
Research & Development	40.03	50.01	39.18	37.45	27.84	28.54
Other Operating Expenses	31.33	22.45	18.74	17.64	17.02	24.3
Operating Expenses	518.91	501.41	481.06	478.49	425.08	483.64
Operating Income	144.45	240.61	280.8	115.45	-7.63	163.83
Interest Expense	-	-0.67	-0.46	-0.02	-0.17	-0.95
Interest & Investment Income	8.61	12.09	2.74	2.97	4.32	4.52
Currency Exchange Gain (Loss)	0.42	0.42	1.38	-0.18	-1.01	-0.01
Other Non Operating Income (Expenses)	2.08	3.28	-7.91	-0.46	-0.17	-0.32
EBT Excluding Unusual Items	155.56	255.73	276.56	117.77	-4.66	167.07
Impairment of Goodwill	-67.51	-67.51	-	-23.17	-668.75	-21.6
Gain (Loss) on Sale of Investments	-12.87	-18.43	-11.97	-9.67	-1.57	-
Gain (Loss) on Sale of Assets	0	0.25	17.77	-0	-0.04	0.05
Asset Writedown	-1.65	-0.78	-1.4	-2.72	-0.05	-0.1
Other Unusual Items	14.35	7.76	9.58	11.34	9.97	14.64
Pretax Income	87.88	177.02	290.54	93.54	-665.09	160.06
Income Tax Expense	46.79	56.31	77.49	27.43	19.38	34.19
Earnings From Continuing Operations	41.1	120.71	213.05	66.1	-684.47	125.87
Minority Interest in Earnings	4.45	5.49	5.74	0.38	-3.19	-5.53
Net Income	45.55	126.2	218.79	66.48	-687.66	120.33
Net Income to Common	45.55	126.2	218.79	66.48	-687.66	120.33
Net Income Growth	-81.82%	-42.32%	229.10%	-	-	-19.32%
Shares Outstanding (Basic)	421	407	405	391	402	401
Shares Outstanding (Diluted)	421	407	405	391	402	401
Shares Change (YoY)	3.90%	0.48%	3.60%	-2.75%	0.26%	-0.50%
EPS (Basic)	0.11	0.31	0.54	0.17	-1.71	0.30
EPS (Diluted)	0.11	0.31	0.54	0.17	-1.71	0.30
EPS Growth	-82.50%	-42.59%	217.65%	-	-	-18.92%
Free Cash Flow	68.33	85.04	268.89	51.03	97.91	159.27
Free Cash Flow Per Share	0.16	0.21	0.66	0.13	0.24	0.40
Dividend Per Share	0.110	0.110	-	-	-	0.070
Dividend Growth	-	-	-	-	-	-12.50%
Gross Margin	58.25%	61.37%	61.31%	56.38%	53.71%	64.39%
Operating Margin	12.68%	19.90%	22.60%	10.96%	-0.98%	16.29%
Profit Margin	4.00%	10.44%	17.61%	6.31%	-88.47%	11.97%
Free Cash Flow Margin	6.00%	7.03%	21.64%	4.84%	12.60%	15.84%
EBITDA	238.52	333.39	371.87	202.41	78.44	245.52
EBITDA Margin	20.95%	27.57%	29.93%	19.21%	10.09%	24.42%
D&A For EBITDA	94.07	92.78	91.06	86.96	86.07	81.69
EBIT	144.45	240.61	280.8	115.45	-7.63	163.83
EBIT Margin	12.68%	19.90%	22.60%	10.96%	-0.98%	16.29%
Effective Tax Rate	53.24%	31.81%	26.67%	29.33%	-	21.36%
Revenue as Reported	1,139	1,209	1,243	1,054	777.3	1,006
Advertising Expenses	-	74.99	59.7	69.59	51.49	43.89

Updated Oct 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.